Stemcell, 100-1650, Enzalutamide

Elicit anti-tumor effects in a variety of cancers with Enzalutamide, a potent and selective androgen receptor (AR) antagonist (IC50 = 36 nM in LNCaP cells). AR signaling has diverse biological functions and is thought to be involved in tumor development, particularly in prostate cancer (Davey & Grossmann. Clin Biochem Rev, 2016). With a strong binding affinity for ARs, Enzalutamide prevents AR translocation to the nucleus, inhibits AR binding to chromosomal DNA, and prevents the recruitment of coactivators (Saad. Ther Adv Urol, 2013; Tran et al. Science, 2009).

Enzalutamide has been used for:

CANCER RESEARCH

· Cause tumor regression in mouse xenograft models of castration-resistant prostate cancer (Guerrero et al. Prostate, 2013; Tran et al. Science, 2009).

· Cause cell apoptosis and reduce cell migration and invasion in AR-positive bladder cancer cell lines (Deng et al. Cell Death Differ, 2021; Kawahara et al. Urol Oncol, 2016).

· Inhibit growth of HER2+ breast cancer cells in vitro and reduce tumor growth in a mouse xenograft model (He et al. Sci Reports, 2017).